Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a r… Read more
Castle Biosciences Inc (CSTL) - Total Liabilities
Latest total liabilities as of September 2025: $95.74 Million USD
Based on the latest financial reports, Castle Biosciences Inc (CSTL) has total liabilities worth $95.74 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Castle Biosciences Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Castle Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Castle Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Castle Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Itcen Co. Ltd
KQ:124500
|
Korea | ₩850.59 Billion |
|
Hangzhou XZB Tech Co Ltd
SHG:603040
|
China | CN¥231.24 Million |
|
Hsino Tower Group Co., Ltd.
SHG:601096
|
China | CN¥5.35 Billion |
|
Zhejiang Guyuelongshan Shaoxing Wine Co Ltd
SHG:600059
|
China | CN¥514.00 Million |
|
Regis Healthcare Ltd
AU:REG
|
Australia | AU$2.12 Billion |
|
Mavi Giyim Sanayi Ve Ticaret AS
IS:MAVI
|
Turkey | TL11.01 Billion |
|
Zhejiang Jiaao Enprotech
SHG:603822
|
China | CN¥5.68 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Castle Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Castle Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Castle Biosciences Inc (2017–2024)
The table below shows the annual total liabilities of Castle Biosciences Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $75.40 Million | +21.47% |
| 2023-12-31 | $62.07 Million | +28.83% |
| 2022-12-31 | $48.18 Million | -5.22% |
| 2021-12-31 | $50.83 Million | +115.05% |
| 2020-12-31 | $23.64 Million | -31.75% |
| 2019-12-31 | $34.63 Million | +6.65% |
| 2018-12-31 | $32.47 Million | +34.79% |
| 2017-12-31 | $24.09 Million | -- |